vimarsana.com

Latest Breaking News On - Red hill biopharma - Page 1 : vimarsana.com

Cosmo announces successful Phase III clinical trial of Lumeblue™ in China

Cosmo Pharmaceuticals N.V. / Key word(s): Study resultsCosmo announces successful Phase III clinical trial of Lumeblue™ in China 14.12.2022 / 06:00 GMT/BST Dublin, Ireland – 14 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful phase III clinical trial of Lumeb.

Falk gmbhHazel winchesterCosmo pharmaceuticalsnv keyCosmo pharmaceuticalsRed hill biopharma ltdHoldings limitedChina medical systemRed hill biopharma

Cosmo Pharmaceuticals N.V. / Key word(s): Regulatory ApprovalCosmo announces FDA grants orphan-drug designation ofrifamycin for treatment of pouchitis 20.10.2022 / 06:00 GMT/BSTDublin, Ireland – 20 October 2022. Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announces that the FDA has granted the orpha.

City ofUnited kingdomDeutsches eigenkapitalforumFalk gmbhHazel winchesterCosmo pharmaceuticalsnv keyCosmo pharmaceuticalsCredit suisse equity forum switzerlandRed hill biopharma ltdRegulatory approvalOrphan drug designationRed hill biopharma

GI Genius™ named to FORTUNE 2022 Change the World list

Cosmo Pharmaceuticals N.V. / Key word(s): MiscellaneousGI Genius™ named to FORTUNE 2022 “Change the World” list 12.10.2022 / 06:00 GMT/BSTDublin, Ireland – 12 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that Medtronic, its global partner for GI Genius™, published a medi.

City ofUnited kingdomDeutsches eigenkapitalforumFalk gmbhHazel winchesterCosmo pharmaceuticalsnv keyCosmo pharmaceuticalsCredit suisse equity forum switzerlandRed hill biopharma ltdRed hill biopharma

Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement for Winlevi® in German

Cosmo Pharmaceuticals N.V. / Key word(s): Agreement04-Oct-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland & Heppenheim, Germany – 04 October 2022: Cosmo Phar.

Rheinland pfalzUnited statesSun pharmaBeyvers gmbDiana harbortConsilium gmbHazel winchesterFalk gmbhFlorence wicheMarkus rudolphCosmo pharmaceuticalsUnited states food drug administrationCosmo dermatology divisionCosmo pharmaceuticalsnv keyHead of global sales international businessInfectopharm group

Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to i

Cosmo Pharmaceuticals N.V. / Key word(s): Agreement26-Jul-2022 / 06:01 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland and Mumbai, India – 26 July 2022: Sun Pharmaceutical In.

New south walesUnited statesCity ofUnited kingdomNew zealandSun pharmaNimish desaiGaurav chughClin aesthet dermatolDiana harbortHazel winchesterDeutsches eigenkapitalforumFalk gmbhAalok shanghviGerlonim cortexoloneCosmo pharmaceuticals

vimarsana © 2020. All Rights Reserved.